“Over the last few years, we have been executing their vision and goal to grow our generics business in India and globally,” he said. “As we look to the next decade, I hope in the future we can further grow in the generics business as we transition into drug innovation.”
The 34-year-old leader of the Ahmedabad-based pharma-to-power generation conglomerate has set himself an ambitious target of taking Torrent Pharma into the top three in the Indian pharmaceutical market. Mehta spearheaded Torrent Pharma’s nearly $3-billion (`. 25,689-crore) acquisition of Mumbai-based JB Pharma in 2025 in one of the largest in the Indian pharma space. He is now focused on consolidating the company’s leadership in the `. 650-crore market for weightloss drug semaglutide.
“In today’s modern and disruptive world, the only way to survive and thrive is to keep up with the latest trends and try to stay ahead. You will not stay ahead all the time, as competition is intense, but it is the few right calls that make the difference,” Mehta had told ET in the run-up to the award show. “Our goal as the next generation is to maximise the percentage of right calls versus wrong.